Composition containing BTK inhibitor and application thereof
Patent Information
- Application Number
- CN202410586295.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
[0063] Additional aspects and advantages of the invention will be set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention.
Smart Images

Figure BDA0004835751660000061 
Figure BDA0004835751660000121 
Figure BDA0004835751660000131
Abstract
Description
[0001] Priority information
[0002] This application claims priority and benefits of patent application 202310539559.0 filed with the State Intellectual Property Office of China on May 12, 2023, and the entire text of which is incorporated herein by reference. Technical Field
[0003] The present invention relates to the field of biopharmaceutical technology. Specifically, the present invention relates to a composition containing a BTK inhibitor and uses thereof. Background Art
[0004] Irreversible Bruton's Tyrosine Kinase (BTK) inhibitors can block multiple immune signaling pathways in immune cells other than T cells and terminally differentiated plasma cells, such as blocking B cell receptors in B cells, inhibiting plasma cell differentiation and antibody production, blocking IgG-mediated FCGR activation, phagocytosis and inflammatory mediators in monocytes and macrophages, blocking IgE-mediated FCR activation and degranulation in mast cells and basophils, and inhibiting cell activation, recruitment, and oxidation in neutrophils.
[0005] The pathogenesis of urticaria can be divided into two categories, allergic reaction and non-allergic reaction. The allergic reaction type is mainly type I, which is the effect of antigen and antibody IgE on mast cells and basophils, causing their granules to fall off and produce a series of chemical mediators (histamine and histamine-like substances) to be released. This causes capillary dilation, increased permeability, smooth muscle spasm, increased glandular secretion, etc. The non-allergic reaction type is caused by certain biological, chemical and physical factors that can directly act on mast cells and basophils, causing them to release granules and cause the disease. Studies have verified that BTK is necessary for Fc receptor signaling in human mast cells, and BTK inhibitors can lead to the inhibition of the FcγR pathway, thereby inhibiting IgE-induced mast cell degranulation and the release of histamine and inflammatory factors. BTK targeted drugs have been verified in non-allergic subjects and allergic subjects as effective inhibitors of IgE-dependent histamine release in human basophils.
[0006] Therefore, there is an urgent need to develop a composition containing a BTK inhibitor for treating BTK-related immune system diseases. Summary of the invention
[0007] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides a composition containing a BTK inhibitor, which has high stability and can be used to treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0008] In one aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof. The composition of the present invention uses (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof (referred to herein as the raw material or compound (I)) as an active ingredient, which can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0009] According to an embodiment of the present invention, the above-mentioned composition may further include at least one of the following technical features:
[0010] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 1 to 800 mg.
[0011] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 800 mg.
[0012] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 10 to 800 mg.
[0013] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 100 mg. According to an embodiment of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is 1% to 40%, preferably 4% to 35%.
[0014] According to an embodiment of the present invention, it further includes a pharmaceutically acceptable excipient.
[0015] According to an embodiment of the present invention, the pharmaceutically acceptable excipient includes a filler. Thus, the active ingredient is combined with the filler to overcome the problem of reduced stability of the composition, and the composition has the advantages of high stability. According to an embodiment of the present invention, the filler includes at least one of pregelatinized starch, mannitol, microcrystalline cellulose and lactose.
[0016] According to an embodiment of the present invention, the filler is pregelatinized starch.
[0017] According to an embodiment of the present invention, the filler is mannitol.
[0018] According to an embodiment of the present invention, the filler is selected from microcrystalline cellulose and / or mannitol.
[0019] According to an embodiment of the present invention, the filler is microcrystalline cellulose and optionally mannitol.
[0020] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (1-40):(60-99).
[0021] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-35):(61-91).
[0022] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (16-35):(61-79).
[0023] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-10):(80-91).
[0024] According to an embodiment of the present invention, the pharmaceutically acceptable excipient further includes at least one of a disintegrant, a lubricant, a surfactant and a binder.
[0025] According to an embodiment of the present invention, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate and cross-linked polyvinylpyrrolidone.
[0026] According to an embodiment of the present invention, the disintegrant is cross-linked sodium carboxymethyl cellulose.
[0027] According to an embodiment of the present invention, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc.
[0028] According to an embodiment of the present invention, the lubricant is magnesium stearate.
[0029] According to an embodiment of the present invention, the binder is selected from at least one of hydroxypropyl methylcellulose, povidone K30 and hydroxypropyl cellulose.
[0030] According to an embodiment of the present invention, the binder includes hypromellose and / or povidone K30.
[0031] According to an embodiment of the present invention, the surfactant is selected from sodium dodecyl sulfate and / or Tween 80.
[0032] According to an embodiment of the present invention, the surfactant is sodium dodecyl sulfate.
[0033] According to an embodiment of the present invention, in the composition, the surfactant and the binder exist simultaneously.
[0034] According to an embodiment of the present invention, the composition does not include micro powder silica gel.
[0035] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is (1-40):(1-10), preferably (4-35):(4-6).
[0036] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is (1-40):(0.1-1), preferably (4-35):(0.1-0.6).
[0037] According to an embodiment of the present invention, the weight ratio of the surfactant to the binder is (0.1-1):(1-5).
[0038] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the surfactant is (1-40):(0.1-1), preferably (4-35):(0.4-0.6).
[0039] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the adhesive is (1-40):(1-5), preferably (4-35):(1-2).
[0040] According to an embodiment of the present invention, the composition is an oral preparation.
[0041] According to an embodiment of the present invention, the oral preparation is a capsule or a tablet.
[0042] According to an embodiment of the present invention, the composition is a capsule.
[0043] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant and a lubricant.
[0044] According to an embodiment of the present invention, the composition does not include a surfactant.
[0045] According to an embodiment of the present invention, the composition includes: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of a filler, 4 to 6 parts by weight of a disintegrant, and 0.1 to 0.6 parts by weight of a lubricant.
[0046] According to an embodiment of the present invention, the composition includes: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate.
[0047] According to an embodiment of the present invention, the composition includes: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate.
[0048] According to an embodiment of the present invention, the composition includes: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate.
[0049] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant and a lubricant.
[0050] According to an embodiment of the present invention, the composition includes: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 80 to 90 parts by weight of a filler, 4 to 6 parts by weight of a disintegrant, 1 to 2 parts by weight of a binder, 0.4 to 0.6 parts by weight of a surfactant, and 0.1 to 0.6 parts by weight of a lubricant.
[0051] According to an embodiment of the present invention, the composition includes: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65 to 70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 1 to 2 parts by weight of hypromellose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and 0.1 to 0.6 parts by weight of magnesium stearate.
[0052] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of pregelatinized starch, one of mannitol and microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when sampled at 60°C for 10 days, and can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0053] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0054] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0055] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0056] According to an embodiment of the present invention, the capsule is composed of the following components: 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 78 to 79 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate.
[0057] According to an embodiment of the present invention, the capsule is composed of the following components: 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate.
[0058] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65 to 70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, 1 to 2 parts by weight of hydroxypropyl methylcellulose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when placed at 60°C for 10 days, and can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0059] In another aspect of the present invention, the present invention provides a use of the aforementioned composition or the aforementioned capsule in preparing a medicament for treating and / or preventing immune system diseases.
[0060] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.
[0061] According to an embodiment of the present invention, the autoimmune disease includes autoimmune disease, urticaria, skin inflammation and / or eczema.
[0062] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.
[0063] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0065] Figure 1The dissolution results of Prescriptions 1 to 5 in Example 1 of the present invention are shown below;
[0066] Figure 2 The dissolution results of Prescription A, Prescription B and Prescription C-2 in Example 3 of the present invention are shown below;
[0067] Figure 3 is the C of the raw material capsule after a single administration of each dosage group in the clinical trial of Test Example 1 of the present invention max correlation with drug substance dosage;
[0068] Figure 4 The AUC of the raw material capsule after a single administration of each dose group (10-100 mg) in the clinical trial of Test Example 1 of the present invention is 0-t correlation with drug substance dosage;
[0069] Figure 5 The AUC of the raw material capsule after a single administration of each dose group (200-800 mg) in the clinical trial of Test Example 1 of the present invention is 0-t correlation with drug substance dosage;
[0070] Figure 6 The change of BTK target site occupancy rate over time in each dosage group of the raw material capsule in the clinical trial of Test Example 1 of the present invention;
[0071] Figure 7 All subjects C in the clinical trial of Test Example 1 of the present invention max Curve fitting with BTK target occupancy max;
[0072] Figure 8 AUC of all subjects in the clinical trial of Test Example 1 of the present invention last Curve fitting with BTK target site occupancy max. DETAILED DESCRIPTION
[0073] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0074] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0075] Where a numerical range is provided, it is understood that, unless the context clearly indicates otherwise, to one tenth of the unit of the lower limit, intervening values between the upper and lower limits of the range and any other stated or intervening values in the range are encompassed within the present invention. These smaller range limits may be independently included within the smaller range and are also encompassed within the present invention, subject to any specific exclusion of limitation within the range. Where the range includes one or both of the limits, the range excluding either or both of those including the limits is also encompassed within the present invention.
[0076] The term “comprise” or “include” is an open expression, that is, including the contents specified in the present invention but not excluding other contents.
[0077] The terms "optionally", "optional" or "optionally" mean that the subsequently described event or circumstance can but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur.
[0078] The term "pharmaceutically acceptable" means that the substance or composition must be chemically and / or toxicologically compatible with the other ingredients of the formulation and / or the mammals treated therewith. Preferably, the "pharmaceutically acceptable" of the present invention refers to those approved by federal regulatory agencies or national governments or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopeias for use in animals, particularly humans.
[0079] The term "pharmaceutically acceptable salt" refers to organic salts and inorganic salts of compound (I) of the present invention. Pharmaceutically acceptable salts are well known to those skilled in the art. In some embodiments, the pharmaceutically acceptable salts of the present invention include, but are not limited to, hydrochloride, benzenesulfonate, p-toluenesulfonate, sulfate, hydrobromide, etc.
[0080] For the excipients and other pharmaceutically acceptable excipients or processes mentioned herein, reference can be made to a large number of literatures on this subject and will not be described in detail here.
[0081] As used herein, the term "treatment" refers to the use of drugs to obtain the desired pharmacological and / or physiological effects. The effect may be preventive in terms of completely or partially preventing a disease or its symptoms, and / or may be therapeutic in terms of partially or completely curing a disease and / or the adverse effects caused by the disease. "Treatment" as used herein covers diseases in mammals, particularly humans, and includes: (a) preventing the occurrence of a disease or condition in an individual who is susceptible to the disease but has not yet been diagnosed with the disease; (b) inhibiting the disease, such as blocking the progression of the disease; or (c) alleviating the disease, such as alleviating symptoms associated with the disease. "Treatment" as used herein covers any medication that administers a drug or compound (I) to an individual to treat, cure, alleviate, improve, mitigate or inhibit an individual's disease, including but not limited to administering a drug containing compound (I) described herein to an individual in need.
[0082] The present invention provides a composition containing a BTK inhibitor and uses thereof, which will be described in detail below.
[0083] Composition
[0084] In one aspect of the present invention, the present invention proposes a composition. According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof. The composition of the present invention uses (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof as an active ingredient, which can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0085] As used herein, the term "active ingredient" or "active agent" refers to a substance used for treatment (e.g., human treatment, veterinary treatment) (including preventive and therapeutic treatment). Active ingredients include any substance used as a drug for treating, preventing, delaying, alleviating or ameliorating a disease, condition or disorder.
[0086] The structure of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one is shown below:
[0087]
[0088] According to an embodiment of the present invention, the above-mentioned composition may further include at least one of the following technical features:
[0089] According to an embodiment of the present invention, the composition of the present invention contains a suitable amount of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof. The suitable amount is an effective dose of the compound (I), and the effective dose is safe and effective.
[0090] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 1 to 800 mg.
[0091] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 800 mg.
[0092] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 10 to 800 mg.
[0093] According to an embodiment of the present invention, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 100 mg.
[0094] In some optional embodiments of the present invention, in the composition, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 1-5 mg, 1-10 mg, 1-25 mg, 1-50 mg, 1-100 mg, 1-200 mg, 1-400 mg, 1-600 mg, 1-800 mg, 5-10 mg, 5-25 mg, 5-50 mg, 5-100 mg, 5-200 mg, 5-400 mg, 5-600 mg, 5-800 mg, 10-25 mg, 10-50 mg, 10-100mg, 10-200mg, 10-400mg, 10-600mg, 10-800mg, 25-50mg, 25-100mg, 25-200mg, 25-400mg, 25-600mg, 25-800mg, 50-100mg, 50-200mg, 50-4 00mg, 50-600mg, 50-800mg, 100-200mg, 100-400mg, 100-600mg, 100-800mg, 200-400mg, 200-600mg, 200-800mg, 400-600mg, 400-800mg, 600-800mg.
[0095] In some optional embodiments of the present invention, in the composition, the content of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof is 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg or 800 mg.
[0096] In some optional embodiments of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is 1% to 40%, preferably 4% to 35%.
[0097] In some optional embodiments of the present invention, the mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one in the composition is 1% to 40%, preferably 4% to 35%, 4% to 6%, 16% to 17%, 28% to 34% or 4% to 10%.
[0098] It should be noted that when the active ingredient in the composition is a pharmaceutically acceptable salt of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one, the content of the salt can be converted according to the ratio of the molecular weight of the free compound (I) to the corresponding salt.
[0099] According to an embodiment of the present invention, it further includes a pharmaceutically acceptable excipient.
[0100] According to an embodiment of the present invention, the pharmaceutically acceptable excipient includes a filler. Thus, the combination of the active ingredient and the filler can well overcome the problem of reduced stability of the composition, and the composition has the advantages of high stability.
[0101] According to an embodiment of the present invention, the filler includes at least one of pregelatinized starch, mannitol, microcrystalline cellulose and lactose.
[0102] According to an embodiment of the present invention, the filler is pregelatinized starch.
[0103] According to an embodiment of the present invention, the filler is mannitol.
[0104] According to an embodiment of the present invention, the filler is microcrystalline cellulose and / or mannitol.
[0105] According to an embodiment of the present invention, the filler is microcrystalline cellulose and optionally mannitol.
[0106] According to an embodiment of the present invention, the filler is microcrystalline cellulose.
[0107] According to an embodiment of the present invention, the fillers are microcrystalline cellulose and mannitol.
[0108] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (1-40):(60-99).
[0109] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-35):(61-91).
[0110] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (16-35):(61-79).
[0111] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-10):(80-91).
[0112] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-6):(88-91).
[0113] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (16-17):(78-79).
[0114] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (28-34):(61-67).
[0115] Thus, the amount and rate of impurities generated during storage of the composition can be effectively reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0116] According to an embodiment of the present invention, the pharmaceutically acceptable excipients include at least one of a disintegrant, a lubricant, a surfactant and a binder. By adding the above-mentioned excipients, the stability of the composition can be further improved.
[0117] According to an embodiment of the present invention, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium starch glycolate and cross-linked polyvinylpyrrolidone.
[0118] According to an embodiment of the present invention, the disintegrant is cross-linked sodium carboxymethyl cellulose.
[0119] According to an embodiment of the present invention, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc.
[0120] According to an embodiment of the present invention, the lubricant is magnesium stearate.
[0121] According to an embodiment of the present invention, the binder is selected from at least one of hydroxypropyl methylcellulose, povidone K30 and hydroxypropyl cellulose.
[0122] According to an embodiment of the present invention, the binder includes hypromellose and / or povidone K30.
[0123] According to an embodiment of the present invention, the surfactant is selected from sodium dodecyl sulfate and / or Tween 80.
[0124] According to an embodiment of the present invention, the surfactant is sodium dodecyl sulfate.
[0125] According to an embodiment of the present invention, in the composition, the surfactant and the binder exist simultaneously.
[0126] According to an embodiment of the present invention, in the composition, the filler is microcrystalline cellulose and mannitol, and the surfactant and the binder are present at the same time.
[0127] According to an embodiment of the present invention, the composition does not include micro powder silica gel.
[0128] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is (1-40):(1-10), for example (1-40):(1-9), (1-40):(1-8), (1-40):(1-7), (1-40):(1-6), (1-40):(1-5), (1-40): (2~9), (1~40): (2~8), (1~40): (2~7), (1~40): (2~6), (1~40): (2~5), (1~40): (3~9), (1~40): (3~8), (1~40): (3~7), (1~40): (3~6), (1~40): (3~5), (1~40): (4~9), (1~40): (4~8), (1~40): (4~7), (4~35): (4~6), (4~35): (4~5).
[0129] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is (1-40):(0.1-1), for example (1-40):(0.1-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.5), (1-40):(0.2-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.5), (1-40):(0.2-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.7), (1-40):(0.1-0.8 ... .2~0.8), (1~40): (0.2~0.7), (1~40): (0.2~0.6), (1~40): (0.2~0.5), (1~40): (0.3~0.9), (1~40): (0.3~0.8), (1~40): (0.3~0.7), (1~40): (0.3~0.6), (1~40): (0.3~0.5), (1~40): (0.4~0.9), (1~40): (0.4~0.8), (1~40): (0.4~0.7), (1~40): (0.4~0.6), (1~40): (0.4~0.5).
[0130] According to an embodiment of the present invention, the weight ratio of the surfactant to the binder is (0.1-1):(1-5).
[0131] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the surfactant is (1-40):(0.1-1), for example (1-40):(0.1-0.9), (1-40):(0.1-0.8), (1-40):(0.1-0.7), (4-35):(0.1-0.6), (1-40):(0.1-0.5), (1-40):(0.2-0.9), (1-40):(0.2-0.8), (1~40): (0.2~0.7), (1~40): (0.2~0.6), (1~40): (0.2~0.5), (1~40): (0.3~0.9), (1~40): (0.3~0.8), (1~40): (0.3~0.7), (1~40): (0.3~0.6), (1~40): (0.3~0.5), (1~40): (0.4~0.9), (1~40): (0.4~0.8), (1~40): (0.4~0.7), (1~40): (0.4~0.6), (4~35): (0.4~0.6), (1~40): (0.4~0.5).
[0132] According to an embodiment of the present invention, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof and the adhesive is (1-40):(1-5), for example (1-40):(1-4), (1-40):(1-3), (4-35):(1-2), (1-40):(2-5), (1-40):(2-4), (1-40):(2-3).
[0133] According to an embodiment of the present invention, the composition is an oral preparation, such as a solid oral preparation.
[0134] In this article, the term "oral preparation" refers to a preparation form that is administered orally and absorbed into the blood in the gastrointestinal tract, including but not limited to tablets, granules, capsules, oral solutions, etc.
[0135] The term "solid oral dosage form" refers to tablets, dispersible tablets, fast-dissolving tablets, fast-dissolving tablets, fast-melting tablets, orodispersible tablets, freeze-dried units, porous tablets, conventional tablets, coated tablets, uncoated tablets, enteric-coated tablets (gastro-resistant tablets), effervescent tablets, soluble tablets, chewable tablets, oral lyophilisates, powders, oral powders, pills, capsules and / or granules. In some embodiments, the solid oral dosage form is a capsule. In some embodiments, the solid oral dosage form is a tablet.
[0136] According to an embodiment of the present invention, the solid oral preparation is a capsule or a tablet.
[0137] According to an embodiment of the present invention, the composition is a capsule.
[0138] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant and a lubricant.
[0139] According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant and a lubricant, and does not include a surfactant. Thus, the amount and rate of impurities generated during storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0140] According to an embodiment of the present invention, the composition does not include a surfactant.
[0141] According to an embodiment of the present invention, in the composition, the filler is pregelatinized starch, mannitol, microcrystalline cellulose, or lactose, and the composition does not include a surfactant.
[0142] According to an embodiment of the present invention, the composition includes: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of a filler, 4 to 6 parts by weight of a disintegrant, and 0.1 to 0.6 parts by weight of a lubricant. Thus, the amount and rate of impurities generated during storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0143] Herein, the term "parts by weight" refers to the mass fraction obtained by comparing the mass of a component of the composition with the mass of other components. For example, the filler content is 61 to 91 parts by weight, which means that the mass fraction obtained by comparing the mass of the filler with the mass of other components of the composition is 61 to 91 parts by weight.
[0144] According to an embodiment of the present invention, the composition comprises: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0145] According to an embodiment of the present invention, the composition includes: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0146] According to an embodiment of the present invention, the composition includes: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0147] According to an embodiment of the present invention, the composition includes: 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 78 to 79 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate.
[0148] According to an embodiment of the present invention, the composition includes: 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate.
[0149] According to an embodiment of the present invention, the composition comprises: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0150] According to an embodiment of the present invention, the composition includes: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated. According to an embodiment of the present invention, the composition comprises: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated. According to an embodiment of the present invention, the composition includes: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated. According to an embodiment of the present invention, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant, and a lubricant. Thus, the amount and rate of impurities generated during storage of the composition can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0151] According to an embodiment of the present invention, the composition includes: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 80 to 90 parts by weight of a filler, 4 to 6 parts by weight of a disintegrant, 1 to 2 parts by weight of a binder, 0.4 to 0.6 parts by weight of a surfactant, and 0.1 to 0.6 parts by weight of a lubricant. Thus, the amount and rate of impurities generated during storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0152] According to an embodiment of the present invention, the composition includes: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65 to 70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 1 to 2 parts by weight of hydroxypropyl methylcellulose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and 0.1 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the combination can be reduced, the stability of the composition can be improved, and the storage of the composition can be facilitated.
[0153] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of pregelatinized starch, one of mannitol and microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when sampled at 60°C for 10 days, and can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0154] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0155] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0156] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0157] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0158] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0159] According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 5 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88 to 91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.4 to 0.6 parts by weight of magnesium stearate.
[0160] According to an embodiment of the present invention, the capsule is composed of the following components: 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 78 to 79 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0161] According to an embodiment of the present invention, the capsule is composed of the following components: 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0162] According to an embodiment of the present invention, the capsule is composed of the following components: 28 to 29 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 65 to 67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0163] According to an embodiment of the present invention, the capsule is composed of the following components: 33 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 62 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, and 0.1 to 0.3 parts by weight of magnesium stearate. Thus, the amount and rate of impurities generated during the storage of the capsule can be reduced, the stability of the capsule can be improved, and the storage of the capsule can be facilitated.
[0164] In another aspect of the present invention, the present invention proposes a capsule. According to an embodiment of the present invention, the capsule is composed of the following components: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazine-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65 to 70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked carboxymethyl cellulose sodium, 1 to 2 parts by weight of hydroxypropyl methylcellulose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, and 0.1 to 0.6 parts by weight of magnesium stearate. The composition of the present invention has the advantages of high stability, and its total impurity content is ≤5.0% when placed at 60°C for 10 days, and can be used to prevent or treat immune system diseases, such as chronic spontaneous urticaria in adults.
[0165] In addition, those skilled in the art will appreciate that the features and advantages described above for the composition are also applicable to the capsule, and will not be described in detail here.
[0166] Pharmaceutical use
[0167] In another aspect of the present invention, the present invention provides a use of the aforementioned composition or the aforementioned capsule in preparing a medicament for treating and / or preventing immune system diseases.
[0168] In this article, "skin allergic disease" and "skin allergic reaction" are synonymous without special explanation.
[0169] According to an embodiment of the present invention, the immune system disease includes an autoimmune disease and / or a skin allergy disease.
[0170] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or skin allergy disease.
[0171] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.
[0172] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or urticaria.
[0173] According to an embodiment of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.
[0174] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.
[0175] Methods of treating or preventing immune system diseases
[0176] In another aspect of the present invention, the present invention provides a method for treating and / or preventing immune system diseases. According to an embodiment of the present invention, the method comprises: administering a pharmaceutically acceptable amount of the aforementioned composition or capsule to a subject.
[0177] Composition provided by the present invention or capsule can be given to the patient separately, also can be given or co-administered with other active agents.Term " give together " and " combine " are included in the situation that there is no concrete time limit and give two or more therapeutic agents simultaneously or sequentially.In certain embodiments, before giving the second therapeutic agent or afterwards (for example, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks ago), simultaneously or afterwards (for example, 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks or 12 weeks later) give the first reagent.
[0178] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or skin allergy disease.
[0179] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis, urticaria, skin inflammation and / or eczema.
[0180] According to an embodiment of the present invention, the immune system disease includes rheumatoid arthritis and / or urticaria.
[0181] According to an embodiment of the present invention, the skin allergy disease includes urticaria, skin inflammation and / or eczema.
[0182] According to an embodiment of the present invention, the urticaria is chronic spontaneous urticaria.
[0183] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0184] For the preparation method of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one (hereinafter referred to as the API or compound (I)) in the following examples, please refer to Scheme 29 and Example 32 in CN105837576A.
[0185] Example 1: Preparation of API capsules
[0186] 1.1 The components of Formulations 1 to 5 in the capsules are shown in Table 1. The preparation method of the capsules is as follows:
[0187] The API was crushed for 5 seconds and then dispersed with a 60-mesh screen. The crushed API was then mixed with each excipient (except magnesium stearate), mixed at 15 rpm (which can be any speed in the range of 5-30 rpm) for 15 minutes (which can be any time in the range of 5-30 minutes), and then magnesium stearate was added, mixed at 5 rpm (which can be any speed in the range of 5-30 rpm) for 15 minutes (which can be any time in the range of 5-30 minutes), and finally the mixed drug was filled into a capsule (Suzhou Capsule Co., Ltd.) and the dissolution rate of the sample was measured. The capsules of the five prescriptions were then placed in a 60°C oven for a pre-stability test, and samples were taken after 10 days to measure the detection of related substances in the samples.
[0188] Table 1: Formulas of Prescriptions 1 to 5
[0189]
[0190]
[0191] 1.2 Dissolution rate detection
[0192] The dissolution rate of the prepared capsules was measured by the USP paddle method using a dissolution test apparatus in a 1000 mL glass container with a lid. The capsules were placed in 900 mL of a solution with a pH of 1.2 at a temperature of 37°C (±5°C) and stirred at 50 rpm. The dissolution results are shown in Figure 1 From the dissolution results, it can be seen that the differences between the prescriptions 1 to 5 of the present invention are not large.
[0193] 1.3 Detection of related substances
[0194] Chromatographic conditions:
[0195] Chromatographic column: Agilent Zorbax SB-C18 (4.6 mm × 150 mm, 5 μm) or equivalent; column temperature: 30 ° C; flow rate: 1.0 mL / min; detection wavelength: 220 nm; injection volume: 10 μL; mobile phase A: pH 6.0 ammonium phosphate buffer solution; mobile phase B: acetonitrile; diluent: acetonitrile: pure water 50 / 50 (v / v).
[0196] Gradient elution program:
[0197] Time (min) Mobile phase A (%) Mobile phase B (%) 0.00 95 5 20.00 61 39 24.00 59 41 30.00 59 41 30.01 44 56 38.00 44 56 50.00 10 90 52.00 10 90 52.01 95 5 60.00 95 5
[0198] The test results of the relevant substances are shown in Table 2. It was found that, except for prescription 4, prescriptions 1 to 3 and prescription 5 all met the requirements of the total impurity limit.
[0199] Table 2: Impurity changes at 60℃ for 10 days
[0200] Related substances Limit requirements Prescription 1 Prescription 2 Prescription 3 Prescription 4 Prescription 5 RRT 1.12(Impurity M) ≤0.50% 0.21% 0.20% 0.23% 0.21% 0.22% RRT 1.30(Impurity E) ≤0.80% 0.28% 0.30% 0.32% 0.43% 0.33% Other impurities — 3.05% 3.77% 3.21% 5.89% 4.17% Total Miscellaneous ≤5.0% 3.54% 4.27% 3.76% 6.53% 4.72%
[0201] RRT: relative retention time
[0202] 1.4 The oral bioavailability of the capsules of Prescription 1 and Prescription 3 was further studied in beagle dogs: 6 beagle dogs (3 males and 3 females) were designed, provided by Beijing Marshall Biological Resources Co., Ltd. A single oral administration, the dosage was 2 mg / kg. The sampling time points were designed: before medication, 5min, 15min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, 24h after medication.
[0203] From the in vivo bioavailability data in Table 3, it can be seen that the absolute oral bioavailability of Prescription 1 and Prescription 3 for beagle dogs is in the range of 22% to 26%.
[0204] Table 3: Oral bioavailability parameters of different capsule formulations in beagle dogs
[0205]
[0206]
[0207] Note: C max represents the peak concentration; T max represents the peak time; AUC represents the area under the plasma concentration-time curve, where AUC 0-last Represents the area under the blood drug concentration-time curve from time zero to the last time point, AUC 0-inf It represents the area under the plasma drug concentration-time curve from time zero to infinite time. 1 / 2 MRT stands for terminal elimination half-life 0-last Represents the average residence time from zero time to the last time point, MRT 0-inf represents the average residence time from time zero to time infinity. F(%)a represents the absolute bioavailability.
[0208] Example 2: Further screening of API capsule formulations containing different excipients
[0209] On the basis of prescription 1, a certain amount of micro-powder silica gel was added to obtain prescription 6, and the specific formula is shown in Table 4. The preparation method is shown in Example 1, and then the capsules of prescription 6 were placed in a 60°C oven for a preliminary stability test. After 10 days, samples were taken to determine the detection of related substances in the samples (see Example 1 for the detection method), and the detection results are shown in Table 5. The results show that compared with prescription 1 without micro-powder silica gel, the addition of micro-powder silica gel did not improve the stability of the drug, but accelerated the degradation of the drug.
[0210] Table 4: Formula of Prescription 6
[0211]
[0212] Table 5: Impurity changes of prescription 6 after 10 days of staking at 60℃
[0213] Related substances Limit requirements Prescription 6 (60℃) RRT 1.12(Impurity M) ≤0.50% 0.15% RRT 1.32(Impurity E) ≤0.80% 0.60% Other impurities — 5.54% Total Miscellaneous ≤5.0% 6.29%
[0214] RRT: relative retention time
[0215] Example 3: Further screening of formulations of API capsules of different specifications
[0216] In order to match capsules of different specifications (or BTK inhibitor capsules), the dosage of each component of the prescription was further adjusted based on prescription 1, as shown in Table 6. The preparation method is shown in Example 1, and the dissolution of the sample is determined (see Example 1 for the detection method). The detection results are shown in Figure 2 The results showed that there was no significant difference in the dissolution of capsule prescriptions with specifications of 5mg, 50mg and 100mg (taking prescription C-2 as an example); and the solubility of prescription C-1 and prescription C-2 in a medium with a pH value of 1.2 was compared. The results showed that the solubility of prescription C-1 in 30 minutes was 76.3%, and the solubility of prescription C-2 in 30 minutes was 79.3%. There was not much difference in the dissolution of the two prescriptions.
[0217] Then the capsules of each prescription were placed in a 60°C oven for a pre-stability test, and samples were taken after 10 days to determine the related substances of the samples (see Example 1 for the detection method), and the detection results are shown in Table 7. It was found that the impurity content of prescription C-1 and prescription C-2 was not much different. The impurity changes of the 100mg prescription in this embodiment were shown using prescription C-2 as an example; among them, the impurity growth of the three specifications of 5mg, 50mg and 100mg (taking prescription C-2 as an example) capsules at 60°C for 10 days was within the range of 2.4% to 2.5%, which was within the limit requirement (≤5.0%).
[0218] Table 6: 5mg, 50mg and 100mg capsule prescriptions
[0219]
[0220] Table 7: Impurity changes of prescription A, prescription B, and prescription C-2 after 10 days of staking at 60°C
[0221] Related substances Source of impurities Limit requirements 5mg Specification 50mg Specification 100mg Specification RRT 0.77 (impurity BK02) API Process Impurities ≤0.15% Not detected Not detected Not detected RRT0.96(Impurity D) API Process Impurities ≤0.15% 0.09% 0.09% 0.10% RRT 1.12(Impurity M) API Process Impurities ≤0.50% 0.22% 0.22% 0.22% RRT1.25(Impurity E) API Process Impurities ≤0.80% 0.12% 0.10% 0.09% RRT1.31(Impurity H) Degradation of impurities ≤1.00% 0.70% 0.70% 0.74% RRT1.54(Impurity F) Degradation of impurities ≤1.50% 1.07% 0.95% 0.94% Other single impurities — ≤0.15% 0.09% 0.10% 0.11% Total impurities — ≤5.0% 2.5% 2.4% 2.4%
[0222] RRT: relative retention time
[0223] Test Example 1: In vivo efficacy study of prescription A, prescription B, prescription C-1, C-2 and API
[0224] 1. Mouse Model
[0225] 1.1 Evaluation of the in vivo efficacy model of collagen-induced arthritis (CIA) in mice
[0226] In this step, the solvent is prepared according to a volume ratio of DMSO: 40% HP-β-CD: water of 5:15:80 (10 ml of DMSO, 30 ml of 40% HP-β-CD, and 160 ml of MilliQ pure water are mixed and then dispensed).
[0227] In this step, the preparation method of the bulk drug solution is as follows: weigh a certain amount of the bulk drug, add the calculated volume of DMSO, and shake and mix until dissolved. Then add DMSO solution, 40% HP-β-CD and MilliQ pure water (wherein the volume ratio of DMSO: 40% HP-β-CD: water = 5:15:80). The solution is fully mixed, and then diluted three times to the dosing concentration, and finally a bulk drug solution with a specific dosing concentration is obtained.
[0228] In this step, the preparation method of CC-292 solution is as follows: a certain amount of CC-292 compound (purity of 98.7%) is weighed, and the calculated volume of DMSO is added, and the mixture is shaken and mixed until dissolved. Then DMSO solution, 40% HP-β-CD and MilliQ pure water (wherein the volume ratio of DMSO: 40% HP-β-CD: water = 5:15:80) are added. The solution is fully mixed, and then diluted three times to the dosing concentration, and finally a CC-292 solution of a specific dosing concentration is obtained.
[0229] The collagen-induced mouse arthritis model is a classic animal model used to evaluate the efficacy of drugs for the treatment of rheumatoid arthritis (RA). Its pathogenesis and symptoms are significantly correlated with RA. The clinical symptoms of arthritis in mice are induced by injecting collagen emulsion into the tail of mice. The specific steps are as follows:
[0230] DBA / 1 mice were randomly divided into 6 groups, 10 mice in each group except the blank control group (5 mice). The mice in the normal group did not need to be immunized, and the other groups were immunized, wherein the first immunization day was recorded as day 0, and the subsequent days were marked in sequence. After DBA / 1 mice were anesthetized with isoflurane, 50 microliters of the prepared collagen emulsion (containing 200 micrograms of CII) were injected subcutaneously in the tail (2-3 cm from the base of the tail). On the 21st day, the same volume of collagen emulsion was injected into the tail in the same way.
[0231] On day 28, when the average clinical score reached 1 to 2 points, the mice were re-randomized into 4 treatment groups (10 mice per group) and a blank solvent control group (10 mice per group) according to body weight and score. The relevant dosage design of the drug substance and the control compound CC-292 was determined based on the results of the previous pilot experiment. The first group was a normal group (no drugs or solvents were fed); the second group was given a blank solvent control (the solvent was 10 mL / kg); the third group was given CC-292 solution, the dose of CC-292 was 3 mg / kg (the concentration of CC-292 solution was 0.3 mg / mL, and the administration volume was 10 mL / kg); the fourth, fifth, and sixth groups were given API solution, the doses of API were 1 mg / kg (the concentration of API solution was 0.1 mg / mL, and the administration volume was 10 mL / kg), 3 mg / kg (the concentration of API solution was 0.3 mg / mL, and the administration volume was 10 mL / kg), and 10 mg / kg (the concentration of API solution was 1 mg / mL, and the administration volume was 10 mL / kg). The drug was administered once a day for a total of 14 days. The volume of oral administration was 10 mL / kg. After the administration, the clinical score curve of each animal in each group was analyzed to calculate the area under the curve (AUC). The inhibition rate of each administration group relative to the blank solvent control was calculated by the average AUC between groups.
[0232] Clinical observation: From 7 days before immunization to the 21st day after immunization, the basic health status and weight changes of DBA / 1 mice were observed daily (recorded twice a week). After the 22nd day, the health status, disease incidence, and weight changes of mice were observed daily (recorded every two days) until the end of the experiment.
[0233] Clinical scoring: After boosting immunity, the mice were observed for disease on a daily basis. When the mice began to develop disease (clinical symptoms of arthritis appeared), they were scored on a scale of 0-4 points according to the degree of lesions (redness, swelling, joint deformation), with the highest score for each limb being 4 points and the highest score for each animal being 16 points. The scores were performed at least three times a week.
[0234] Pathology: On the 42nd day, the mice were euthanized. The two hind limbs of the mice were taken, soaked in 10% formalin solution, decalcified with formic acid solution, embedded in paraffin, sliced, stained with hematoxylin-eosin (HE), and observed under a microscope. The degree of joint damage was evaluated from four aspects: inflammatory cell infiltration, pannus formation, cartilage damage, and bone resorption, and scored according to the standard of 0-4 points.
[0235] The experimental results showed that compared with the normal group, the average body weight of each immune group decreased significantly after administration. After the 33rd day, the average body weight of the 1mg / kg treatment group of the API solution remained basically the same, while the average body weight of the 3mg / kg and 10mg / kg treatment groups of the API solution increased, and the body weight of the 10mg / kg group showed significant differences compared with the blank solvent control group on the 37th and 40th days, showing a good weight recovery effect.
[0236] The inflammation inhibition rate of the 1mg / kg API solution group was 65.5%, the inhibition rate of the 3mg / kg API solution group was 82.4%, and the inhibition rate of the 10mg / kg API solution group was 83.9%. Compared with the blank solvent control, the three dosages showed extremely significant differences (p<0.001) and showed a certain dose-effect relationship. The inflammation inhibition rate of the 3mg / kg CC-292 solution group was 29.1%. Compared with the blank solvent control, the 3mg / kg CC-292 solution group had no significant difference.
[0237] Pathological studies showed that only slight inflammation was observed in the foot joint bone tissue of the three dose groups (1, 3, 10 mg / kg) of the raw material solution, and the histopathological score decreased with the increase of the dose, which was dose-dependent, and there was a very significant difference in the histopathological score compared with the blank solvent control group. The reference control drug 3mg / kg CC-292 solution administration group showed certain inflammation and more bone tissue damage, and there was no significant difference in the histopathological score compared with the blank solvent control group.
[0238] 1.2 Evaluation of drug efficacy in passive cutaneous anaphylaxis (PCA) animal model
[0239] Passive skin allergy test, also known as PCA reaction, is a local allergic reaction caused by antibodies that bind to the same or different animal tissues. The PCA animal model in this application is a passive sensitization in which IgE binds to specific receptors of skin mast cells. When allergens are stimulated, local mast cells release allergic mediators, thereby increasing local vascular permeability. It is often used as a drug efficacy model for urticaria indications, and can also prove the anti-allergic effect of drugs during the onset of skin inflammation and eczema. The specific steps are as follows:
[0240] In this step, the preparation method of the bulk drug solution is: the solvent is 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A certain amount of the bulk drug is weighed, dissolved in the calculated volume of DMSO, and fully mixed with the calculated HP-β-CD and Kolliphor EL plus deionized water to finally obtain a bulk drug solution with a dosing concentration.
[0241] In this step, prednisone was formulated with 0.5% CMC-Na (sodium carboxymethylcellulose).
[0242] In this step, the preparation method of cetirizine is: the solvent is 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A certain amount of cetirizine is weighed, dissolved in the calculated volume of DMSO, and fully mixed with the calculated HP-β-CD and Kolliphor EL plus deionized water to finally obtain the dosing concentration of cetirizine (the cetirizine in the subsequent test examples is all cetirizine containing solvent).
[0243] In this step, the preparation method of LOU-064 is as follows: the solvent is 5% DMSO (dimethyl sulfoxide) + 15% 40% HP-β-CD (hydroxypropyl-β-cyclodextrin) + 10% 0.4% Kolliphor EL (commercially available) + 70% water. A certain amount of LOU-064 is weighed, dissolved in the calculated volume of DMSO, and fully mixed with the calculated HP-β-CD and Kolliphor EL plus deionized water to finally obtain a LOU-064 solution of the dosing concentration. The pH of LOU-064 is adjusted to obtain a clear solution.
[0244] The mouse PCA model was induced by anti-DNP IgE. Specifically, BALB / c mice were divided into 9 groups, namely, a normal control group (no medication, injection or feeding of any solvent), a model group (no medication, injection or feeding of any solvent), a prednisone group (10 mg / kg, QD (once a day) for 3 consecutive days, where the concentration of prednisone was 1 mg / mL and the administration volume was 10 mL / kg), a cetirizine group (20 mg / kg, QD for 3 consecutive days, where the concentration of cetirizine was 2 mg / mL and the administration volume was 10 mL / kg), low-medium dose groups of the test substance LOU-064 (15, 45 mg / kg, administered BID (twice a day) for 3 consecutive days, wherein the concentration of LOU-064 was 1.5 and 4.5 mg / mL, respectively, and the administration volume was 10 mL / kg) and low-medium-high dose groups of the bulk drug solution (15, 45 and 90 mg / kg, administered BID for 3 consecutive days, wherein the concentration of the bulk drug solution was 1.5, 4.5 and 9 mg / mL, respectively, and the administration volume was 10 mL / kg), 9 mice in each group, administered by gavage, for a total of 4 days. On the third day of administration, anti-DNP IgE (Sigma-Aldrich) was injected into the left ears of 8 groups of mice (no normal control group), and the right ears of the 8 groups and the left and right ears of the normal control group were injected with the same volume of PBS to allow it to bind to mast cells. Then anti-DNP IgE injected 24h on the 4th day, with antigen (DNP-HAS, Sigma) and pigment Evan's Blue (Sigma) mixed solution (0.25mL / only, iv) injected into tail vein (normal control group injected antigen and pigment Evan's Blue mixed solution of same volume), antigen will react with the antibody attached on mast cells to cause local allergic reaction, local vascular permeability increases, pigment penetrates into tissue, by measuring the content of local pigment after 30min, judge reaction intensity. Collect left and right ear dye extraction, specific wavelength measures the absorbance of Evan's blue, calculate its content according to standard curve (referring to Table 8, wherein the right ear Evan's Blue concentration of each group and the normal control group left ear all have no significant difference), assess the pharmacodynamic effect of each tested drug in PCA animal model.
[0245] Table 8
[0246]
[0247]
[0248] The experimental results showed that compared with the normal control group, the ear weight of the modeling side (left side) of the model group mice was significantly increased, and the Evan's blue content in the ear was significantly increased. Compared with the model group, the three dose groups of the API significantly reduced the Evan's Blue content in the model animal's modeling ears, and the efficacy was significant. The low and medium dose groups showed a dose-effect relationship, and the effect was equivalent to LOU-064 at the same dose. The low dose was equivalent to prednisone and cetirizine. Therefore, the API has a good therapeutic effect on anti-DNP IgE-induced passive skin allergic reactions in mice.
[0249] 2. Patient clinical trials
[0250] 2.1 Test methods
[0251] This test case recruited 96 healthy Chinese people aged 18-45 as subjects. The trial included 8 dose groups, each with a total of 12 people, who were randomly divided into groups, 10 of whom received bulk drug capsules (i.e., the test group) and 2 received placebo capsules (not containing bulk drug ingredients, i.e., the control group or placebo group). The bulk drug capsules used the prescription A capsules, prescription B capsules, or prescription C-2 capsules prepared in Example 3; the placebo capsules used the prescription A' capsules, prescription B' capsules, or prescription C-2' capsules. The preparation of prescription A' capsules, prescription B' capsules, or prescription C-2' capsules specifically refers to the preparation method of Example 3, wherein the specific difference between prescription A' capsules and prescription A capsules is that they do not contain bulk drug ingredients, the specific difference between prescription B' capsules and prescription B capsules is that they do not contain bulk drug ingredients, and the specific difference between prescription C-2' capsules and prescription C-2 capsules is that they do not contain bulk drug ingredients. The dosages involved in this embodiment are all the amounts of bulk drugs.
[0252] Based on safety and exploratory factors, the human MRSD (maximum recommended starting dose) of the API capsule used in the test case was set at 10 mg, and the human maximum recommended dose was set at 800 mg. A total of 8 dose groups were set between the initial dose and the maximum dose (see Table 9 for the dose escalation scheme for the clinical trial): 10 mg (the test group took 2 capsules of prescription A, and the placebo group and the test group took 2 capsules of prescription A'), 25 mg (the test group took 5 capsules of prescription A, and the placebo group and the test group took 5 capsules of prescription A'), 50 mg (the test group took 1 capsule of prescription B, and the placebo group and the test group took 1 capsule of prescription B'), 100 mg (the test group took 1 capsule of prescription C-2, and the placebo group and the test group took 1 capsule of prescription C-2') , 200mg (the experimental group took 2 prescription C-2 capsules, and the placebo group took 2 prescription C-2' capsules), 400mg (the experimental group took 4 prescription C-2 capsules, and the placebo group took 4 prescription C-2' capsules), 600mg (the experimental group took 6 prescription C-2 capsules, and the placebo group took 6 prescription C-2' capsules), 800mg (the experimental group took 8 prescription C-2 capsules, and the placebo group took 8 prescription C-2' capsules). Single-dose safety and tolerability tests were conducted group by group.
[0253] Subjects fasted for 10 hours before administration and took a single oral dose of the API capsule or placebo capsule at the prescribed dose on the morning of the test day. No water was allowed within 2 hours after administration and no food was allowed within 4 hours after administration. Blood sample collection: 3.0 ml of venous blood was collected before administration (within 45 minutes) and at 10 minutes, 20 minutes, 0.5 hours, 1 hour, 1.5 hours, 1.75 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours, 6 hours, 8 hours, 12 hours, 16 hours, 24 hours, 36 hours, 48 hours, and 72 hours after administration. Urine sample collection: Urine samples were collected before administration (within 2 hours) and at 0-2 hours, 2-4 hours, 4-8 hours, 8-12 hours, 12-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours after administration. Feces collection: Feces were collected before administration (within 3 days) and at 0-24h, 24-48h, and 48-72h after administration.
[0254] Table 9: Dose escalation plan for a single-dose clinical trial of bulk drug capsules in Phase I
[0255]
[0256]
[0257] 2.2 Statistical analysis methods
[0258] Per-protocol set: All subjects who met the inclusion criteria, did not meet the exclusion criteria, had no major protocol deviations, and completed medication, pharmacokinetic and pharmacodynamic sampling, and safety assessments according to the protocol constituted the per-protocol population of this study.
[0259] 2.2.1 Statistical analysis of pharmacokinetics The analysis was performed using the protocol-compliant set. WinNonlin 6.4 was used to process the plasma concentration data of the API capsules over time. The non-compartmental model was used to calculate the main pharmacokinetic parameters of each subject. The power function model was used to analyze the relationship between dose and C max , AUC 0-t linear relationship.
[0260] 2.2.2 Statistical analysis of pharmacodynamics was performed using the per-protocol set.
[0261] ELISA was used to detect the receptor occupancy of compound (I) in human peripheral blood mononuclear cell lysate. This analytical method is to use ELISA to perform relative quantitative determination of BTK in human peripheral blood mononuclear cells (PBMC).
[0262] The PBMC lysate containing BTK is incubated with compound (I), and no compound (I) is added as a control. After incubation with biotin-labeled compound (I) (Biotinlated compound (I)), it is added to a well plate pre-coated with streptavidin. When compound (I) is incubated with PBMC lysate, it binds to BTK, thereby preventing BTK from binding to biotin-labeled compound (I). Since the complex cannot bind to the well plate, it is difficult to generate a response signal.
[0263] Rabbit anti-BTK primary antibody is incubated with the above samples and will bind to BTK. Tetramethylbenzidine (TMB) is the substrate of HRP coupled to anti-rabbit secondary antibody. The reaction is terminated by sulfuric acid. After color development, the absorbance value is measured at a wavelength of 450nm. 620nm can be used for background correction. The content of free BTK is proportional to the absorbance value, so the content of BTK can be indirectly detected. Data processing is as follows:
[0264] Free BTK (%) = 100% × [(S 样本X -S 样品X+化合物(I) ) / (S 第1天给药前 -S 第1天给药前+化合物(I) )]
[0265] Note: S 样本X : represents the absorbance value of the sample X to be tested;
[0266] S 样品X+化合物(I) : represents the absorbance value of the sample X after adding compound (I) [10uM], which is used as the background reference of the sample;
[0267] S 第1天给药前 : represents the signal value of the sample before the first administration;
[0268] S 第1天给药前+化合物(I) : represents the absorbance value after adding compound (I) [10uM] to the sample before the first administration, which serves as the background reference of the sample.
[0269] BTK occupancy % = 100% - free BTK %.
[0270] The Chi-Square test was used to analyze the differences in BTK target site occupancy rates among the different dose test groups; Logistic Regression was used to analyze the relationship between dose, blood drug concentration and BTK target site occupancy rate.
[0271] 2.2.3 Safety, Tolerability Assessment and Statistical Analysis
[0272] Safety data set: includes all subjects who received at least one dose and have safety data after administration. Safety evaluation indicators include adverse events / adverse reactions, laboratory tests, electrocardiograms, vital signs, physical examinations, thyroid ultrasound, upper abdominal CT, and chest X-rays. All subjects in the placebo group were combined into one group. The safety analysis set was used, and the safety indicators were mainly described by statistics. Comparative analysis was performed before and after treatment in each treatment group, between each dose test group, and between the test group and the placebo group.
[0273] 2.3 Results Analysis
[0274] 2.3.1 Pharmacokinetics
[0275] After a single dose of API capsules was administered to healthy subjects, the CL / F, Vz / F, and T of API capsules in eight dose groups were 1 / 2 , MRT 0-t , MRT 0-∞ and T max The difference was statistically significant (p<0.05), and the difference in CLr was not statistically significant (p>0.05) (see Table 10 for details). In the dosage range of 10mg to 800mg, the βC max =1.0740, in the range of 0.8 to 1.25. Linear equation slope βC max The 90% confidence interval of the drug was 1.0247-1.1234, and part of it fell within the judgment interval of 0.9491-1.0509, indicating that within the dosage range of 10 mg to 800 mg, the C max With linear pharmacokinetic trend (see Figure 3 and Table 11). Also, at 10-100 mg ( Figure 4and Table 12) and 200-800 mg ( Figure 5 and Table 13), AUC 0-t It shows a linear pharmacokinetic trend.
[0276] Table 10: Pharmacokinetic parameters of the API capsules after administration
[0277]
[0278] Note: Data are expressed as mean ± standard deviation.
[0279] C max represents the peak concentration; T max represents the peak time; z represents the terminal elimination rate constant; AUC represents the area under the plasma concentration-time curve, where AUC 0-t Represents the area under the blood drug concentration-time curve from zero time to the last quantifiable blood sampling point, AUC 0-∞ Represents the area under the plasma drug concentration-time curve from time zero to infinite time, AUC _%Extrap Residual area percentage (AUC _%Extrap =[(AUC 0-∞ -AUC 0-t ) / AUC 0-∞ ]×100%). 1 / 2 represents the terminal elimination half-life, V z / F represents the apparent volume of distribution in the terminal phase after non-intravenous administration, CL / F represents the apparent systemic clearance of the drug from plasma after oral administration, and MRT last It represents the average residence time from zero to the minimum detectable blood drug concentration. INF_obs represents the average residence time extrapolated from zero to infinity, and CLr represents the renal clearance rate of the drug from plasma.
[0280] Table 11: C of 10-800 mg API capsules after single administration max Linear evaluation results of the power function model with dose
[0281]
[0282] Power function model formula: PK = α * dose β .
[0283] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r = D H / D L , D H Indicates high dose, DL Indicates low dose, θ L =0.8,θ H =1.25.
[0284] Table 12: AUC of 10-100 mg API capsules after single administration to healthy subjects 0-t Linear evaluation results of the power function model with dose
[0285]
[0286] Power function model formula: PK = α * dose β .
[0287] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r = D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.
[0288] Table 13: AUC of 200-800 mg API capsules after single administration to healthy subjects 0-t Linear evaluation results of the power function model with dose
[0289]
[0290] Power function model formula: PK = α * dose β .
[0291] Judgment interval calculation formula: 1+Ln(θ L / Ln(r)<β<1+ln(θ H ) / ln(r); where r = D H / D L , D H Indicates high dose, D L Indicates low dose, θ L =0.8,θ H =1.25.
[0292] 2.3.2 Pharmacodynamics
[0293] After a single dose of 10 mg of the API capsule, the maximum BTK target occupancy rate was 58.93%. When a single dose of 25 mg or more was administered, the maximum BTK target occupancy rate was close to 100% (see Figure 6The peak time was 0.5-4h, and the peak time gradually shortened with the increase of dose. After administration of placebo, the BTK target occupancy rate was maintained between 20-30% for most of the time.
[0294] 2.3.3 Relationship between pharmacokinetics and pharmacodynamics
[0295] Based on the pharmacokinetic and pharmacodynamic data obtained for each dose, the quantitative relationship between pharmacokinetics and pharmacodynamics was analyzed.
[0296] The data fitting shows that at lower C max and AUC last Under these conditions, the BTK target occupancy rate can reach nearly 100% (see Figure 7-8 ).
[0297] 2.3.4 Security
[0298] 29 of the 96 subjects experienced 44 adverse events (AEs), of which 1 was a pre-dose adverse event and the remaining 43 were treatment-related adverse events (TEAEs). A total of 35 TEAEs occurred in 25 subjects (31.3%) in the experimental group, and 8 TEAEs occurred in 4 subjects (25%) in the placebo group. Except for one subject in the placebo group who experienced a grade 2 AE of anemia, the rest were grade 1 AEs (see Table 14 for details).
[0299] In the experimental group, except for 2 AEs (upper respiratory tract infection, eyelid surgery) treated with medication and 1 AE (upper respiratory tract infection) treated with medical antipyretic patch, no measures were taken for the remaining AEs and they recovered to normal or baseline levels on their own. Except for 2 nephrolithiasis AEs that were definitely unrelated to the trial drug and were unchanged, the other AEs disappeared. Ten AEs occurred in 9 subjects (11.3%) and were judged to be possibly related to the trial drug and were adverse reactions. The incidence of adverse events in the 50, 100, 200 and 400 mg dose groups in the experimental group was high, all 50%, and no adverse events occurred in the 800 mg dose group. The incidence of AEs in other dose groups was 10-30%. There was no obvious dose-related incidence of adverse events. In the placebo group, except for 1 AE (anemia) treated with medication and 1 AE (dizziness) subject taking oral glucose, no measures were taken for the remaining AEs and they recovered to normal on their own. All AEs disappeared. The incidence of adverse reactions was 12.5% (2 / 16). No SAEs (serious adverse events) occurred in this trial, and no AEs leading to withdrawal from the trial occurred (see Tables 15 and 16 for details).
[0300] Table 14: Summary of adverse event incidence during the trial
[0301]
[0302]
[0303] aThe severity of adverse reactions was graded according to CTACE version 4.03
[0304] Table 15: Systemic adverse events in subjects after administration
[0305]
[0306]
[0307] Note: Adverse events were coded according to MedDRA V23.0.
[0308] Table 16: Adverse reactions due to treatment
[0309]
[0310] Note: Adverse events were coded according to MedDRA V23.0.
[0311] In summary, this test case studied the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics of a single oral API capsule in healthy adult subjects. The test results showed that within the range of a single dose of 10 to 800 mg, T max 1.03-2.00h, T 1 / 2 0.847-8.67h, C max The AUC is 46.1-5060 ng / mL, which increases with the increase of dose and has a linear pharmacokinetic trend. 0-t It is 77.7~14392h*ng / m, and increases with the dose in the dose range of 10mg~100mg and 200mg~800mg, with a linear pharmacokinetic trend. CL / F is similar in the low-dose group (10-50mg), and decreases with increasing dose. MRT is short, 1.53~4.25h, and slightly prolonged with increasing dose. The maximum BTK occupancy rate in the 10mg dose group is 58.93%, and the maximum BTK occupancy rate in the 25mg and above dose groups is close to 100%. All AEs in the experimental group were of grade 1 severity, and only one grade 2 AE occurred in the placebo group.
[0312] With the primary efficacy analysis conducted in the fourth week, a Phase IIa clinical trial was designed to evaluate the efficacy and safety of compound (I) after 4 weeks of administration. The Phase IIa clinical trial adopted a randomized, double-blind, placebo-controlled design to evaluate the efficacy and safety of compound (I) in patients. The population included in the trial was patients who had been diagnosed with chronic spontaneous urticaria (CSU) at the time of randomization and met the following requirements: (1) itching and wheals had persisted for at least 6 weeks before screening, despite taking second-generation H1 antihistamines to treat CSU during this period; (2) the 7-day urticaria activity score (UAS7) (range 0-42) was ≥16 points, the 7-day wheal severity score (HSS7) (range 0-21) was ≥6 points, and the 7-day itch severity score (ISS7) (range 0-21) was ≥6 points within 7 consecutive days (-8 to -2 days) before randomization; (3) the duration of CSU before screening was ≥6 months (defined as the onset of CSU determined by the investigator based on all existing supportive records). After randomization, patients received compound (I) or placebo, with a dose of 25 mg twice a day. The preliminary results were evaluated by using UAS7, 7-day pruritus severity score (ISS7), 7-day wheal severity score (HSS7), dermatology life quality index (DLQI), urticaria control test (UCT), and angioedema activity score (AAS7) scales to assess the improvement of urticaria-related symptoms in patients at week 4 or 5 after administration.
[0313] The Phase IIa trial will evaluate the compound (I)'s tendency to improve urticaria-related symptoms in patients with chronic spontaneous urticaria, as well as its safety in patients.
[0314] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0315] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. A composition, characterized in that The invention comprises (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof.
2. The composition according to claim 1, characterized in that The content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 1 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 10 to 800 mg; Preferably, the content of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof is 5 to 100 mg.
3. The composition according to claim 1, characterized in that The mass percentage of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof in the composition is 1% to 40%, preferably 4% to 35%.
4. The composition according to claim 1, characterized in that Further comprising pharmaceutically acceptable excipients; Optionally, the pharmaceutically acceptable excipients include fillers; Optionally, the filler comprises at least one of pregelatinized starch, mannitol, microcrystalline cellulose and lactose; Optionally, the filler is pregelatinized starch; Optionally, the filler is mannitol; Optionally, the filler is microcrystalline cellulose and / or mannitol; Optionally, the filler is microcrystalline cellulose and optionally mannitol; Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (1 to 40):(60 to 99); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-35):(61-91); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (16-35):(61-79); Preferably, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the filler is (4-10):(80-91).
5. The composition according to claim 4, characterized in that The pharmaceutically acceptable excipients further include at least one of a disintegrant, a lubricant, a surfactant and a binder; Optionally, the disintegrant is selected from at least one of cross-linked sodium carboxymethyl cellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone; Optionally, the disintegrant is cross-linked carboxymethyl cellulose sodium; Optionally, the lubricant is selected from at least one of magnesium stearate, calcium stearate and talc; Optionally, the lubricant is magnesium stearate; Optionally, the binder is selected from at least one of hydroxypropyl methylcellulose, povidone K30 and hydroxypropyl cellulose; Optionally, the binder comprises hypromellose and / or povidone K30; Optionally, the surfactant is selected from sodium lauryl sulfate and / or Tween 80; Optionally, the surfactant is sodium lauryl sulfate; Optionally, in the composition, the surfactant and the binder are present simultaneously; Optionally, the composition does not include micronized silica gel; Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the disintegrant is (1-40):(1-10), preferably (4-35):(4-6); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the lubricant is (1-40):(0.1-1), preferably (4-35):(0.1-0.6); Optionally, the weight ratio of the surfactant to the binder is (0.1-1):(1-5); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the surfactant is (1-40):(0.1-1), preferably (4-35):(0.4-0.6); Optionally, the weight ratio of the (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof to the binder is (1 to 40):(1 to 5), preferably (4 to 35):(1 to 2).
6. The composition according to any one of claims 1 to 5, characterized in that The composition is an oral preparation; Optionally, the oral formulation is a capsule or a tablet.
7. The composition according to claim 6, characterized in that The composition is a capsule; Optionally, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, and a lubricant; Optionally, the composition does not include a surfactant; Optionally, the composition comprises: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of filler, 4 to 6 parts by weight of a disintegrant, 0.1 to 0.6 parts by weight of a lubricant; Optionally, the composition comprises: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.6 parts by weight of magnesium stearate; Optionally, the composition comprises: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88-91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.6 parts by weight of magnesium stearate; Optionally, the composition comprises: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88-91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1 to 0.6 parts by weight of magnesium stearate.
8. The composition according to claim 6, characterized in that The composition is a capsule; Optionally, the composition includes (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, a filler, a disintegrant, a binder, a surfactant and a lubricant; Optionally, the composition comprises: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 80 to 90 parts by weight of filler, 4 to 6 parts by weight of a disintegrant, 1 to 2 parts by weight of an adhesive, 0.4 to 0.6 parts by weight of a surfactant, 0.1 to 0.6 parts by weight of a lubricant; Optionally, the composition comprises: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65-70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 1 to 2 parts by weight of hypromellose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, 0.1 to 0.6 parts by weight of magnesium stearate.
9. A capsule, characterized in that It is composed of the following components: 4 to 35 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61 to 91 parts by weight of one of pregelatinized starch, mannitol and microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components composition: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88-91 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.4-0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components composition: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88-91 parts by weight of microcrystalline cellulose, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.4-0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components composition: 4 to 6 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 88-91 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.4-0.6 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: 16 to 17 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 78-79 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: 28 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61-67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: 28 to 29 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 65-67 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1-0.3 parts by weight of magnesium stearate; Optionally, the capsule consists of the following components: 33 to 34 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 61-62 parts by weight of pregelatinized starch, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 0.1 to 0.3 parts by weight of magnesium stearate.
10. A capsule, characterized in that: It is composed of the following components: 4 to 10 parts by weight of (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-(pyridin-2-yloxy)phenyl)-1H-pyrazolo[3,4-d]pyridazin-7(6H)-one or a pharmaceutically acceptable salt thereof, 15 to 20 parts by weight of microcrystalline cellulose, 65-70 parts by weight of mannitol, 4 to 6 parts by weight of cross-linked sodium carboxymethyl cellulose, 1 to 2 parts by weight of hypromellose, 0.4 to 0.6 parts by weight of sodium lauryl sulfate, 0.1 to 0.6 parts by weight of magnesium stearate.
11. Use of the composition according to any one of claims 1 to 8 or the capsule according to any one of claims 9 to 10 in the preparation of a medicament for treating and / or preventing immune system diseases; Optionally, the immune system disease comprises an autoimmune disease and / or a skin allergy disease; Optionally, the immune system disorder comprises rheumatoid arthritis, urticaria, skin inflammation and / or eczema; Optionally, the urticaria is chronic spontaneous urticaria.
Citation Information
Patent Citations
BTK inhibitors
CN105837576A
